UBS AM’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
UBS AM's CTKB Position: Q3 2026 in Review
UBS AM increased its Cytek Biosciences (CTKB) stake by 90% in Q3 2026, buying an estimated $2.49K and bringing the position to 1,108 shares worth $6.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.
UBS AM first reported a position in CTKB in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.28M in Q4 2024. 128 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- UBS AM held 1,108 shares of Cytek Biosciences worth $6.6K as of Q3 2026.
- UBS AM bought 526 Cytek Biosciences shares in Q3 2026, an estimated $2.49K.
- Cytek Biosciences made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3870 holding.
- UBS AM first reported a position in Cytek Biosciences in Q2 2022 and has held it in 17 quarters since.
- UBS AM's Cytek Biosciences position peaked at $1.28M in Q4 2024.
- 128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.